Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation. 2023

Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar 25000, Pakistan.

OBJECTIVE The current coronavirus disease-2019 (COVID-19) pandemic has triggered a worldwide health and economic crisis. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the disease and completes its life cycle using the RNA-dependent RNA-polymerase (RdRp) enzyme, a prominent target for antivirals. In this study, we have computationally screened ∼690 million compounds from the ZINC20 database and 11,698 small molecule inhibitors from DrugBank to find existing and novel non-nucleoside inhibitors for SARS-CoV-2 RdRp. METHODS Herein, a combination of the structure-based pharmacophore modeling and hybrid virtual screening methods, including per-residue energy decomposition-based pharmacophore screening, molecular docking, pharmacokinetics, and toxicity evaluation were employed to retrieve novel as well as existing RdRp non-nucleoside inhibitors from large chemical databases. Besides, molecular dynamics simulation and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method were used to investigate the binding stability and calculate the binding free energy of RdRp-inhibitor complexes. RESULTS Based on docking scores and significant binding interactions with crucial residues (Lys553, Arg557, Lys623, Cys815, and Ser816) in the RNA binding site of RdRp, three existing drugs, ZINC285540154, ZINC98208626, ZINC28467879, and five compounds from ZINC20 (ZINC739681614, ZINC1166211307, ZINC611516532, ZINC1602963057, and ZINC1398350200) were selected, and the conformational stability of RdRp due to their binding was confirmed through molecular dynamics simulation. The free energy calculations revealed these compounds possess strong binding affinities for RdRp. In addition, these novel inhibitors exhibited drug-like features, good absorption, distribution, metabolism, and excretion profile and were found to be non-toxic. CONCLUSIONS The compounds identified in the study by multifold computational strategy can be validated in vitro as potential non-nucleoside inhibitors of SARS-CoV-2 RdRp and holds promise for the discovery of novel drugs against COVID-19 in future.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000092165 Pharmacophore A three-dimensional representation of a molecule that is used for modeling recognition of ligands and macromolecular targets. Pharmacophore Modeling,Modeling, Pharmacophore,Modelings, Pharmacophore
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D012324 RNA-Dependent RNA Polymerase An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293) Nucleoside-Triphosphate:RNA Nucleotidyltransferase (RNA-directed),RNA Replicase,RNA-Dependent RNA Replicase,RNA-Directed RNA Polymerase,RNA Dependent RNA Polymerase,RNA Dependent RNA Replicase,RNA Directed RNA Polymerase,RNA Polymerase, RNA-Dependent,RNA Polymerase, RNA-Directed,RNA Replicase, RNA-Dependent,Replicase, RNA,Replicase, RNA-Dependent RNA
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
January 2022, Journal of biomolecular structure & dynamics,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
August 2022, Journal of molecular modeling,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
January 2022, Journal of biomolecular structure & dynamics,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
May 2021, Journal of molecular liquids,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
December 2023, Journal of biomolecular structure & dynamics,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
April 2023, Journal of molecular modeling,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
December 2022, Journal of molecular graphics & modelling,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
October 2017, Journal of biomolecular structure & dynamics,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
March 2023, Journal of biomolecular structure & dynamics,
Shahkaar Aziz, and Muhammad Waqas, and Tapan Kumar Mohanta, and Sobia Ahsan Halim, and Aqib Iqbal, and Amjad Ali, and Asaad Khalid, and Ashraf N Abdalla, and Ajmal Khan, and Ahmed Al-Harrasi
March 2023, Journal of biomolecular structure & dynamics,
Copied contents to your clipboard!